drugset / Trial / NCT00280605

ALF-ONE : ALFuzosin ONcE Daily

NCT00280605

Phase 4 Completed 200 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

Timeline

Start
2005-08
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alfuzosin Small molecule 10 mg